B L Norton1, M A Bachhuber2, R Singh3, L Agyemang2, J H Arnsten2, C O Cunningham2, A H Litwin4. 1. Division of General Internal Medicine, Montefiore Medical Center, United States. Electronic address: bnorton@montefiore.org. 2. Division of General Internal Medicine, Montefiore Medical Center, United States. 3. New York University, United States. 4. Division of General Internal Medicine, Montefiore Medical Center, United States. Electronic address: alitwin@ghs.org.
Abstract
BACKGROUND: A greater proportion of HCV-infected people who inject drugs (PWID) need to be linked to care for HCV antiviral treatment. This study sets out to evaluate the efficacy of contingency management (CM) for improving HCV linkage to care, treatment initiation, adherence, and cure for PWID recruited from a needle and syringe program. METHODS:Between March 2015 and April 2016, 20 participants were enrolled into the CM arm, and then subsequently enrolled 20 participants in the enhanced standard of care (eSOC) arm. Participants in the eSOC arm received an expedited appointment and a round-trip transit card. Participants enrolled in the CM arm received eSOC plus $25 for up to ten HCV clinical visits and $10 for each returned weekly medication blister pack. Adherence was measured via electronic blister packs. RESULTS: Overall the median age was 47 years; most were men (67%) and Hispanic (69%). There were no significant differences in demographic characteristics between participants in the study arms. In the CM arm 74% were linked to HCV care, compared to 30% in the eSOC arm (p = 0.01). In the CM arm, 75% (9/12) of treatment eligible participants initiated treatment, compared to 100%(4/4) in the eSOC arm (p = 0.53). All patients (9/9) achieved cure in the CM arm, as compared to 75% (3/4) of patients in the eSOC arm. There were no differences in adherence between study arms. CONCLUSIONS: In this pilot study, contingency management led to higher rates of HCV linkage to care for PWID, as compared to standard of care. CM should be considered as a possible intervention to improve the HCV treatment cascade for PWID.
RCT Entities:
BACKGROUND: A greater proportion of HCV-infectedpeople who inject drugs (PWID) need to be linked to care for HCV antiviral treatment. This study sets out to evaluate the efficacy of contingency management (CM) for improving HCV linkage to care, treatment initiation, adherence, and cure for PWID recruited from a needle and syringe program. METHODS: Between March 2015 and April 2016, 20 participants were enrolled into the CM arm, and then subsequently enrolled 20 participants in the enhanced standard of care (eSOC) arm. Participants in the eSOC arm received an expedited appointment and a round-trip transit card. Participants enrolled in the CM arm received eSOC plus $25 for up to ten HCV clinical visits and $10 for each returned weekly medication blister pack. Adherence was measured via electronic blister packs. RESULTS: Overall the median age was 47 years; most were men (67%) and Hispanic (69%). There were no significant differences in demographic characteristics between participants in the study arms. In the CM arm 74% were linked to HCV care, compared to 30% in the eSOC arm (p = 0.01). In the CM arm, 75% (9/12) of treatment eligible participants initiated treatment, compared to 100%(4/4) in the eSOC arm (p = 0.53). All patients (9/9) achieved cure in the CM arm, as compared to 75% (3/4) of patients in the eSOC arm. There were no differences in adherence between study arms. CONCLUSIONS: In this pilot study, contingency management led to higher rates of HCV linkage to care for PWID, as compared to standard of care. CM should be considered as a possible intervention to improve the HCV treatment cascade for PWID.
Authors: Don C Des Jarlais; Ann Nugent; Alisa Solberg; Jonathan Feelemyer; Jonathan Mermin; Deborah Holtzman Journal: MMWR Morb Mortal Wkly Rep Date: 2015-12-11 Impact factor: 17.586
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: Margaret Hellard; Emma McBryde; Rachel Sacks Davis; David A Rolls; Peter Higgs; Campbell Aitken; Alex Thompson; Joe Doyle; Pip Pattison; Garry Robins Journal: Int J Drug Policy Date: 2015-05-21
Authors: Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Natasha K Martin; Alicia Thornton; Matthew Hickman; Caroline Sabin; Mark Nelson; Graham S Cooke; Thomas C S Martin; Valerie Delpech; Murad Ruf; Huw Price; Yusef Azad; Emma C Thomson; Peter Vickerman Journal: Clin Infect Dis Date: 2016-02-16 Impact factor: 9.079
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Camille C Cioffi; Derek Kosty; Christopher G Capron; Hannah F Tavalire; Robert C Barnes; Anne Marie Mauricio Journal: Public Health Rep Date: 2022-03-03 Impact factor: 3.117
Authors: Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Sharleen M Traynor; Lisa R Metsch; Lauren Gooden; Maxine Stitzer; Tim Matheson; Susan Tross; Adam W Carrico; Mamta K Jain; Carlos Del Rio; Daniel J Feaster Journal: Drug Alcohol Depend Date: 2021-02-03 Impact factor: 4.492
Authors: Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami Journal: Hepatol Commun Date: 2020-12-07